Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
92 hedge funds and large institutions have $187M invested in Osiris Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 18 closing their positions.
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
6% more funds holding
Funds holding: 87 → 92 (+5)
2% more capital invested
Capital invested by funds: $184M → $187M (+$3.57M)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
89% less call options, than puts
Call options by funds: $385K | Put options by funds: $3.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$16.6M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$3.95M |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$1.48M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.45M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
-$4.25M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.5M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$1.78M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.7M |
| 5 |
Morgan Stanley
New York
|
-$1.33M |
OSIR Hedge Fund Activity: Q3 2015 in Review
92 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q3 2015, worth a combined $187M — up 1.9% from $184M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new OSIR positions and 18 closed out — a net gain of 5 holders — while 26 added to existing stakes and 27 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $16.6M. The largest seller was Venator Capital Management, exiting entirely with an estimated $4.25M sold.
- 92 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q3 2015, up from 87 in Q2 2015.
- Funds reported $187M of Osiris Therapeutics, Inc. Common Stock stock for Q3 2015, up 1.9% quarter-over-quarter.
- 23 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q3 2015 and 18 closed out, a net change of +5 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q3 2015 was Consonance Capital Management, an estimated $16.6M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q3 2015 was Venator Capital Management, an estimated $4.25M sold.
Based on aggregated 13F filings for Q3 2015.